| Mesenchymal Markers |
| CD44 |
| Cadherin 2 (CDH2) |
| N-cadherin |
| Syndecan-1 |
| Cytoskeletal proteins |
| Actin stress fibers and a-SMA |
| Cytokeratin 14 (CK14) |
| Fibronectin (FN1) |
| FSP-1 |
| Paxillin |
| S100A4 |
| Vimentin (VIM) |
| Vinculin |
| Secreted factors |
| Laminin g2 |
| MUC-1 |
| MUC-4 |
| MUC-16 |
| MMP-2 |
| MMP-3 |
| MMP-9 |
| MMP-14 |
| Transcription factors |
| AP-1 (FoxB, FOSL1/2, Jun, JunB, ATF4) |
| Beta-catenin |
| E2.2/TCF4 |
| E2F1 |
| E47 |
| ETS-1 |
| FOXC2 |
| Goosecoid (GSC) |
| LEF-1 |
| NANOG |
| SIX1 |
| Smad2 |
| Smad3 |
| Smad4 |
| Snail 1 (SNAI1) |
| Snail 2 (SNAI2) |
| SOX4 |
| SOX9 |
| SOX10 |
| TCF3 (E47)/LEF1 |
| Twist1 |
| ZEB1 (dEF-1) |
| ZEB2 |
| Signaling |
| FGF |
| HGF |
| MAPK |
| Notch |
| Ras |
| TGF-beta |
| Wnt |
| Beta-catenin |
Source: Foroni, C., Broggini, M., Generali, D. and Damia, G., 2012. Epithelial–mesenchymal transition and breast cancer: Role, molecular mechanisms and clinical impact. Cancer treatment reviews, 38(6), pp.689-697.